uniQure Filed for Huntington's Approval. Acceptance Is the Catalyst, Analyst Says
uniQure seeks accelerated FDA approval for its Huntington's gene therapy, AMT-130. William Blair resumes coverage with a $73 fair price.
Stocks · News reference
William Blair Reinstates Outperform on uniQure
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
uniQure shares are trading higher after the company announced the submission of a Biologics License Application to the FDA for the accelerated approval of ifezuntirgene inilparvove. The company submitted its Marketing Authorization Application for ifezuntirgene inilparvovec to the MHRA.
uniQure Submits Biologics License Application to FDA for Accelerated Approval of Ifezuntirgene Inilparvovec (AMT-130), Gene Therapy for Huntington’s Disease
uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the submission of a Biologics License Application (BLA) to the United